Cargando…

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer

Detalles Bibliográficos
Autor principal:	Lee, Arnold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783846/ https://www.ncbi.nlm.nih.gov/pubmed/34755245 http://dx.doi.org/10.1007/s11523-021-00854-x

Ejemplares similares

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective
por: Liu, Jinan, et al.
Publicado: (2021)

First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two ‘long responder’ case reports and review of the current literature
por: Ngan, Roger K. C.
Publicado: (2023)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Pagkali, Antonia, et al.
Publicado: (2022)

Niraparib for ovarian cancer
Publicado: (2021)

Correction to: Short‑term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
por: Wang, Zhi, et al.
Publicado: (2022)

Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
por: Zhao, Minmin, et al.
Publicado: (2023)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2023)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
por: Barretina-Ginesta, Maria-Pilar, et al.
Publicado: (2022)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review
por: Tao, Mengyu, et al.
Publicado: (2020)

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
por: Sisay, Mekonnen, et al.
Publicado: (2017)

Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
por: Cui, Yuzhong, et al.
Publicado: (2022)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
por: Takehara, Kazuhiro, et al.
Publicado: (2021)

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
por: Starks, David, et al.
Publicado: (2023)

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer
por: Ramalingam, Suresh S., et al.
Publicado: (2021)

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
por: Reverdy, Thibaut, et al.
Publicado: (2020)

An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
por: Akay, Melek, et al.
Publicado: (2021)

How to start niraparib in real-world Asian ovarian cancer patients?
por: Hong, Sook-Hee
Publicado: (2021)

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
por: Liu, Huiwen, et al.
Publicado: (2023)

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
por: Wallace, Katrine, et al.
Publicado: (2019)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
por: Lorusso, Domenica, et al.
Publicado: (2022)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
por: del Campo, Josep M., et al.
Publicado: (2019)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022)

Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib
por: Wang, Junjian, et al.
Publicado: (2021)

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2020)

Correction to: Outcome quality standards in advanced ovarian cancer surgery
por: Llueca, Antoni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cj80059vrqma0huos0cad2g2g3